Loading...
Infections with multidrug-resistant organisms are rising worldwide, spurring the need for new antibiotics to treat them; however, the high cost of developing new agents must be offset by manufacturer profitability. In an NIH-supported study, investigators used administrative data from 619 U.S. hospitals between 2016 and 2021 to retrospectively evaluate use of seven recently FDA-approved antibiotics with activity against multidrug-resistant gram-negative organisms. They focused on use of these agents versus older antibiotics for treating infections with difficult-to-treat (DTR) gram-negative pathogens resistant to first-line beta-lactam antibiotics (penicillins, cephalosporins, and carbapenems), older beta-lactam/beta-lactamase inhibitor com…